

No. 18-817

In the Supreme Court of the United States

HIKMA PHARMACEUTICALS USA INC., AND WEST-WARD
PHARMACEUTICALS INTERNATIONAL LTD., N/K/A HIKMA
PHARMACEUTICALS INTERNATIONAL LTD.,
PETITIONERS

v.

VANDA PHARMACEUTICALS INC.,
RESPONDENT


*ON PETITION FOR A WRIT OF CERTIORARI TO THE UNITED
STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT*

CERTIFICATE OF COMPLIANCE

As required by Supreme Court Rule 33.1(h), I certify that the Supplemental Brief for Petitioners Hikma Pharmaceuticals USA Inc., et al., in the above-captioned case complies with the word limitations and contains 2,943 words, excluding the parts of the reply that are exempted by Supreme Court Rule 33.1(d).

I declare under penalty of perjury that the foregoing is true and correct.

Executed on December 20, 2019.



Steffen N. Johnson